• Home
  • Research areas
    • ADME-Tox
    • Biomarkers
    • Cell Biology and Signalling
    • Cell Sourcing – Cell Culture Technologies
    • Drug Discovery
    • Gene Expression – Molecular Biology
    • Stem Cells
    • Supplying Discovery Tools
  • Contact us
  • Meet the authors
  • Facebook
  • LinkedIn
  • Twitter
  • Vimeo
Home
Research areas
    ADME-Tox
    Biomarkers
    Cell Biology and Signalling
    Cell Sourcing - Cell Culture Technologies
    Drug Discovery
    Gene Expression - Molecular Biology
    Stem Cells
    Supplying Discovery Tools
Contact us
Meet the authors
Tebubio's blog - Acting and reacting in life sciences and biotechnologies
  • Home
  • Research areas
    • ADME-Tox
    • Biomarkers
    • Cell Biology and Signalling
    • Cell Sourcing – Cell Culture Technologies
    • Drug Discovery
    • Gene Expression – Molecular Biology
    • Stem Cells
    • Supplying Discovery Tools
  • Contact us
  • Meet the authors
Supplying Discovery Tools

mRNA Vaccines – The promise of more to come

23/09/2021 by Dimitri Szymczak, PhD No Comments
mRNA Vaccines - the promise of more mRNA applications to come

Propelled into the spotlight by the COVID-19 pandemic, mRNA has become a biological entity of great interest in drug discovery – yet mRNA vaccines are just the promising beginning, leading to more and more discoveries and applications. mRNA demonstrates high potential to cure numerous other diseases, as we invite you to discover in this post – let’s take a look at a number of other mRNA based applications with active R&D, establishing mRNA beyond a current trend.

Continue reading
Supplying Discovery Tools

CleanCap: The new capping standard for self-amplifying mRNA

30/04/2020 by Dimitri Szymczak, PhD 2 Comments

Advances in mRNA Vaccines for Infectious Diseases

It is now admitted that mRNA vaccines provide a safe and long-lasting immune response in humans. Since capping of the mRNA is involved in the protein production into the cells, the capping technologies are of great interest for the development of prophylactic and therapeutic vaccines. In this post, I’ll focus on the CleanCap reagents (Trilink BioTechnologies), and notably the CleanCap AU for the self-amplifying mRNA, as well as their benefits, especially for vaccine approaches against pathogens (including the SARS-CoV-2).

Continue reading
Drug Discovery

alpha-GalCer analog, 7DW8-5 – a potential adjuvant in Cancer Immunotherapy?

01/10/2014 by Philippe Fixe, PhD No Comments

Alpha-Gal-Cer interactions with AP cells and its adjuvant effect

Alpha-Gal-Cer (KRN7000) adjuvant effect in innate and adaptive immunities via dendritic and NKT cells. Source: Alphagalcer.net.

Current cancer vaccine strategies strive to efficiently deliver in situ immunogenic Tumour-Associated Antigens (TAAs) into  functional Antigen-Presenting Cells (APCs).  Stimulated APCs cells then initiate anti-tumour reactions through local and complex immune interactions targeting also the tumour microenvironment.

In this context, Xu et al. have recently developed a new effective oral cancer vaccine platform presenting potent immunogenicity and anti-tumour activity with long-lasting protective memory response (1).

The authors have designed optimized Salmonella-based vectors (Salmonella SPI2-encoded T3SS system) co-administrated with a Natural Killer (NKT) cells ligand (2). The delivery of heterogeneous TAAs into APCs has been proven to display enhanced anti-tumour activity through bacterial expressed TAAs-specific immune reponses.

Chemically synthesized NKT cells ligands (alpha-Galactosylceramide known as the αGalCer KRN7000 or alpha-GalCer) and its superior binding affinity analog 7DW8-5 were already known to enhance the immunogenicity and anti-tumour efficacy of bacterial vaccine vectors (3, 4). α-Gal-Cer is known to exhibit potent antitumor activity in various murine experimental cancer models.

Xu et al. clearly show here the potential interest of 7DW8-5 as a vaccine adjuvant in clinical tumour treatment with oral vaccines.

Specific ligand for human and mouse natural killer T (NKT) cells. α-Gal-Cer (KRN7000) exhibits various immunological effects through NKT cell functions including potent antitumor effect.

α-Gal-Cer (KRN7000) specific ligand for natural killer T (NKT) cells.

Sources:

  1. Xu et al. “Development of an Effective Cancer Vaccine Using Attenuated Salmonella and Type III Secretion System to Deliver Recombinant Tumor-Associated Antigens” (2014) Cancer Res Published Online First September 11, 2014. DOI:10.1158/0008-5472.CAN-14-1169.
  2. Nicol A. et al. “Comparison of clinical and immunological effects of intravenous and intradermal administration of a-galactosylceramide (KRN7000)-pulsed dendritic cells” (2011) Clin Cancer Res, 1;17(15):5140-51. DOI: 10.1158/1078-0432.CCR-10-3105.
  3. Xiong G. et al. “Novel cancer vaccine based on genes of Salmonella pathogenicity island 2” (2010) Int J Cancer,126:2622-34. DOI: 10.1002/ijc.24957.
  4. Li X. et al. “Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant” (2010) Proc Natl Acad Sci U S A 2010;107:13010-5. DOI: 10.1073/pnas.1006662107.

Most popular posts

  • HeLa cells: Origin of this important cell line in life science research
  • How to choose the perfect buffer to get a pure, stabilised, functional protein
  • How to make the challenge of mRNA delivery easy
My Tweets

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookie Policy

Copyright © 2018 - tebu-bio - visit our main website at tebu-bio.com

 

Loading Comments...